RT Journal Article
SR Electronic
T1 Computer-aided medical microbiology monitoring tool: a strategy to adapt to the SARS-CoV-2 epidemic and that highlights RT-PCR consistency
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.27.20162123
DO 10.1101/2020.07.27.20162123
A1 Linda Mueller
A1 Valentin Scherz
A1 Gilbert Greub
A1 Katia Jaton
A1 Onya Opota
YR 2020
UL http://medrxiv.org/content/early/2020/07/29/2020.07.27.20162123.abstract
AB Since the beginning of the COVID-19 pandemic, important health and regulatory decisions relied on SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) results. Our diagnostic laboratory faced a rapid increase in the number of SARS-CoV-2 RT-PCR, with up to 1,007 tests per day. To maintain a rapid turnaround time to support patient management and public health authorities’ decisions, we moved from a case-by-case validation of RT-PCR to an automated validation and immediate transmission of the results to clinicians. To maintain high quality and to track possible aberrant results, we developed a quality-monitoring tool based on a homemade algorithm coded in R.We present the results of this quality-monitoring tool applied to 35,137 RT-PCR results corresponding to 30,198 patients. Patients tested several times led to 4,939 pairwise comparisons; 88% concordant and 12% discrepant. Among the 573 discrepancies, 428 were automatically solved by the algorithm. The most likely explanation for these 573 discrepancies was related for 44.9% of the situations to “Clinical evolution”, 27.9% to “Preanalytical” problems, and 25.3% to “Stochastic”. Finally, 11 discrepant results could not be explained, including 8 received from external partners for which clinical data were not available.The implemented quality-monitoring strategy allowed to: i) assist the investigation of discrepant results ii) focus the attention of medical microbiologists onto results requiring a specific expertise and iii) maintain an acceptable TAT. This work highlighted the high RT-PCR consistency for the detection of SARS-CoV-2 and the importance of automated processes to handle a huge number of samples while preserving quality.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external fundingsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The data were obtained during a quality enhancement project at our institution. According to national law the performance and publishing the results of such a project can be done without asking the permission of the competent research ethics committee; exemption letter provided by the "Commission cantonale d'ethique de la recherche sur l'etre humain" of the Vaud Canton (CER-VD), Lausanne, Switzerland.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available